This study aims to:
1. To evaluate the effectiveness of Immulant ® addition to standard treatment in reducing clinical symptoms of Cryptosporidiosis in immunocompromised children. 2. To measure the changes in parasite count in stool samples after treatment with Immulant ®. 3. To assess the safety and tolerability of Immulant ® in children participating in the study.
Clinical diagnosis of Cryptosporidiosis Disease
Age from 5-12 years
Immunocompromised children
Not receiving any drugs causing immunosuppression
Patients undergoing organ transplantation
Patients suffering from autoimmune diseases.
Patients suffering from hypersensitivity of this plant extract
Single group
Echinacea Extract
DrugImmulant ® (an extract derived from Echinacea purpurea plant)
To measure the changes in parasite count in stool samples after treatment
Click on the lead sponsor to view all of their trials.
